drugset / Trial / NCT00081575

Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia

NCT00081575

Phase 3 Completed 434 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedDouble-blindTreatment

Summary

To compare the efficacy and safety of IV tigecycline to IV levofloxacin in the treatment of subjects with CAP requiring hospitalization.

Timeline

Start
2004-01
Primary completion
2005-03
Completion
2005-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Levofloxacin Small molecule 500 mg Intravenous
Subject Tigecycline Small molecule 50 mg